{"filing":{"accession_number":"0001104659-26-089443","cik":"0001393434","ticker":"OCUL","company_name":"OCULAR THERAPEUTIX, INC","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"tm2621618d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_8k.htm"},"events":[{"id":23291,"run_id":21061,"accession_number":"0001104659-26-089443","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Ocular Therapeutix's financial results for Q2 2026 (quarter ended June 30, 2026), filed on August 3, 2026 under Item 2.02. The press release reports total net revenue of $13.5 million, R\u0026D expenses of $54.1 million, and a net loss of $(78.8) million, along with cash position of $598.6 million and runway into 2028. The disclosure is material as it provides investors with the company's quarterly financial performance and liquidity position.","company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23487,"accession_number":"0001104659-26-089443","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Ocular Therapeutix's financial results for Q2 2026 (quarter ended June 30, 2026), filed on August 3, 2026 under Item 2.02. The press release reports total net revenue of $13.5 million, R\u0026D expenses of $54.1 million, and a net loss of $(78.8) million, along with cash position of $598.6 million and runway into 2028. The disclosure is material as it provides investors with the company's quarterly financial performance and liquidity position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:17:40.248476+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23487,"accession_number":"0001104659-26-089443","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Ocular Therapeutix's financial results for Q2 2026 (quarter ended June 30, 2026), filed on August 3, 2026 under Item 2.02. The press release reports total net revenue of $13.5 million, R\u0026D expenses of $54.1 million, and a net loss of $(78.8) million, along with cash position of $598.6 million and runway into 2028. The disclosure is material as it provides investors with the company's quarterly financial performance and liquidity position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:17:40.248476+00:00","company_name":"OCULAR THERAPEUTIX, INC","ticker":"OCUL","filing_date":"2026-08-03"}]}